US FDA panel backs narrow CV risk reduction claim for Boehringer Ingelheim's Micardis
30 July 2009
Sue Sutter
Boehringer Ingelheim's angiotensin receptor blocker Micardis (telmisartan) should be approved for cardiovascular risk reduction in high-risk patients, but only in those individuals who are intolerant of the ACE inhibitor ramipril, the US
FDA's expert advisors said.
In a seven to zero vote, the...
Please Login to read the full article.
30 July 2009
Sue Sutter
In a seven to zero vote, the...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
